Implementing tuberculosis preventive treatment in high-prevalence settings

Fox, Greg J.; Nguyen, Thi Anh Huong; Coleman, Mikaela; Trajman, Anete; Velen, Kavindhran; Marais, Ben J.

doi:10.1016/j.ijid.2021.02.094

Cited by 9 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…De même, il faut augmenter et généraliser l'accès au traitement préventif pour les populations à risque, notamment les contacts de patients tuberculeux, les enfants exposés à la TB et les personnes vivant avec le VIH [24] . L'arrivée des traitements courts et des approches centrées sur le patient sont autant d’éléments qui favorisent la mise à œuvre à grande échelle de cette stratégie [25] .…”

Section: Discussionunclassified

Perspectives d’élimination de la tuberculose : la stratégie OMS à l’épreuve de la pandémie de COVID-19

Agbota

Bonnet

Lienhardt

2022

Médecine et Maladies Infectieuses Formation

View full text Add to dashboard Cite

Section: Discussionunclassified

Perspectives d’élimination de la tuberculose : la stratégie OMS à l’épreuve de la pandémie de COVID-19

Agbota

Bonnet

Lienhardt

2022

Médecine et Maladies Infectieuses Formation

View full text Add to dashboard Cite

“…Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde pISSN: 2179-5924 in most countries with high TB incidence, only a small proportion of people with LTBI are actually identified, evaluated and treated 5,6 .…”

Section: Rbfhssmentioning

confidence: 99%

Drug utilization studies from secondary databases in latent tuberculosis: a scoping review protocol

MENDES,

GUIMARÃES,

SILVA

et al. 2024

Rev Bras Farm Hosp Serv Saude

View full text Add to dashboard Cite

This article introduces a protocol for a scoping review that aims to map and synthesize Drug utilization studies from secondary databases in latent tuberculosis The protocol is intended to document the processes involved in the methodological planning and execution of a scoping review guided by Joanna Briggs Institute guidelines and developed using the 2015 PRISMA-Protocols (PRISMA-P) checklist. The PCC strategy (population, concept and context) systematized the search for studies published in Pubmed, Scopus, BVS, Embase and Web of Science from January 2015 to December 2022. The selection of articles will be carried out in two steps (titles and abstracts, followed by the assessment of the full text of the articles), by two independent reviewers, with the resolution of disagreements by a third reviewer. The results will be analyzed qualitatively/quantitatively and will be organized by themes. The checklist present in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR) will be used to guide the final review report. We hope that this scoping review will shed light on Drug Utilization Research in the field of latent tuberculosis, which is still understudied, especially in Brazil.

show abstract

“…1 Drug-resistant tuberculosis (DR-TB) remains a public health concern worldwide. 2 , 3 According to the Global Tuberculosis Report 2021, it is estimated that approximately 9 million people developed TB and that 1.5 million died from TB in 2020. 4 The emergence of DR-TB, specifically multidrug-resistant TB (MDR-TB), which is defined as TB resistant to at least isoniazid (INH) and rifampicin (RFP), and extensively drug-resistant TB (XDR-TB), which is defined MDR-TB with additional resistance to any fluoroquinolone and at least one of the three second-line injectable drugs, is a threat to the control of this disease.…”

Section: Introductionmentioning

confidence: 99%

Drug Resistance Patterns and Trends in Patients with Suspected Drug-Resistant Tuberculosis in Dalian, China: A Retrospective Study

Pan¹,

Yu²,

Lu³

et al. 2022

IDR

View full text Add to dashboard Cite

Purpose The emergence of drug-resistant tuberculosis (DR-TB) represents a threat to the control of tuberculosis. This study aimed to estimate the patterns and trends of DR-TB in patients with suspected DR-TB. In addition, risk factors for multidrug-resistant tuberculosis (MDR-TB) were identified among suspected DR-TB patients in Dalian, China. Patients and Methods A total of 5661 patients with suspected DR-TB from Jan 1, 2013 to Dec 31, 2020 were included in the final analysis. The resistance pattern of all resistant strains was determined by drug susceptibility testing (DST) using the conventional Lowenstein-Jensen Proportion Method (LJ). DR-TB trends were estimated from 2013 to 2020. During the research period, the chi-square test was employed to analyze the significance of linear drug-resistance trends across time. Bivariate and multivariate logistic regression were performed to assess factors associated with MDR-TB. Results From 2013 to 2020, the resistance rates of rifampicin (RFP) and isoniazid (INH) decreased significantly, whereas the resistance rates of ethambutol (EMB) and streptomycin (SM) increased in patients with suspected DR-TB. From 2013 to 2020, the prevalence of DR-TB decreased in all patients from 34.71% to 28.01% with an average annual decrease of 3.02%. Among new cases, from 2013 to 2020, the prevalence of DR-TB (from 26.67% to 24.75%), RFP-resistant TB (RR-TB) (from 15.09% to 3.00%) and MDR-TB (from 6.08% to 2.62%) showed a significant downward trend. Among patients with a previous treatment history, DR-TB (from 54.70% to 37.50%), RR-TB (from 44.16% to 11.49%) and MDR-TB (from 26.90% to 10.34%) showed a significant downward trend from 2013 to 2020. Males (AOR 1.28, 95% CI 1.035–1.585), patients 45 to 64 years of age (AOR 1.75, 95% CI 1.342–2.284), patients 65 years and older (AOR 1.65, 95% CI 1.293–2.104), rural residents (AOR 1.24, 95% CI 1.014–1.519) and a previous treatment history (AOR 3.94, 95% CI 3.275–4.741) were risk factors for MDR-TB. Conclusion The prevalence of DR-TB, RR-TB and MDR-TB was significantly reduced from 2013 to 2020. Considerable progress has been made in the prevention and treatment of DR-TB during this period. However, the increasing rate of drug resistance in EMB and SM should be taken seriously. Suspected DR-TB patients who are male, older than 45 years of age, live in rural areas, and have a history of TB treatment should be given priority by health care providers.

show abstract

Implementing tuberculosis preventive treatment in high-prevalence settings

Cited by 9 publications

References 13 publications

Perspectives d’élimination de la tuberculose : la stratégie OMS à l’épreuve de la pandémie de COVID-19

Perspectives d’élimination de la tuberculose : la stratégie OMS à l’épreuve de la pandémie de COVID-19

Drug utilization studies from secondary databases in latent tuberculosis: a scoping review protocol

Drug Resistance Patterns and Trends in Patients with Suspected Drug-Resistant Tuberculosis in Dalian, China: A Retrospective Study

Contact Info

Product

Resources

About